Triglyceride Up-regulates Expression of ABCG1 in PMA-induced THP-1 Macrophages Through Activation of JNK and p38 MAPK Pathways

Jaewon Lim¹, Sung Hoon Kim¹, Yeo Wool Kang¹, Byung Chul Jung¹, Hyun-Kyung Kim², Juyeon Lee¹, Dongsup Lee³, Ki-Jong Rhee¹,† and Yoon Suk Kim¹,†

¹Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Gangwon-do 220-710, Korea
²Department of Biomedical Laboratory Science, College of Natural Science, Gimcheon University, Gimcheon 740-704, Korea
³Department of Clinical Laboratory Science, Hyejeon College, Hongseong, Chungcheongnam-do 350-702, Korea

Triglyceride (TG) can cause death of macrophages and formation of foam cells thereby increasing inflammation in atherosclerotic plaques. Accumulation of cholesterol in macrophages is another critical event that promotes development of inflammatory cardiovascular diseases. Several proteins are known to transport intracellular cholesterol outside of the cell and these proteins are thought to be protective against atherosclerosis pathogenesis. It is unknown whether TG can affect cholesterol efflux in macrophages. In the current study, we examined mRNA expression levels of genes that promote efflux of cholesterol (ABCA1, ABCG1 and SR-B1). We found that TG treated THP-1 macrophages exhibited an increase in ABCG1 expression in a dose- and time-dependent manner. In contrast, the expression of ABCA1 and SR-B1 remained unchanged. To identify cell signaling pathways that participate in up-regulation of ABCG1, THP-1 macrophages were treated with various cell signaling inhibitors. We found that inhibition of the JNK and p38 MAPK pathway completely abrogated up-regulation of ABCG1 whereas inhibition of MEK1 further enhanced ABCG1 expression in TG treated THP-1 macrophages. Also, TG induced phosphorylation of JNK and p38 MAPK in THP-1 macrophages. These results suggest that TG may potentially influence cholesterol efflux in macrophages.

Key Words: THP-1 macrophages, Triglyceride (TG), ABCG1, JNK, p38 MAPK

INTRODUCTION

Triglyceride (TG) is one of the main causes of cardiovascular disease especially atherosclerosis. TG can damage vascular epithelium and cause inflammatory response in immune cells eventually leading to atherosclerosis (Lind, 2003; Aronis et al., 2005; Kastelein et al., 2008). Several studies have shown that addition of exogenous TG results in intracellular accumulation of TG, leading to multiple inflammatory effects in macrophages, such as cell death by nitric oxide (NO) formation and expression of CD markers not expressed in resting macrophages (Aronis et al., 2005; Feingold et al., 2012; Son et al., 2013). In early stages of atherosclerosis, accumulation of cholesterol in macrophages is regarded as another important event that precedes subsequent development of atherosclerosis. Recent studies indicate that cholesterol efflux is thought to be a major...
process involved in plaque formation in atherosclerotic regions (Tall et al., 2008; Moore and Tabas, 2011). Cholesterol homeostasis is a balance between intake/efflux of cholesterol in cells (Daniels et al., 2009). In an epidemiological study of atherosclerosis patients, cholesterol efflux was a strong inverse predictor of disease (Khera et al., 2011). Palmer et al., reported that TG-rich lipoproteins inhibit cholesterol efflux from human macrophage foam cell to promote formation of atherosclerotic lesion (Palmer et al., 2004).

Scavenger receptor class B1 (SR-B1) is a high density lipoprotein (HDL) receptor that induces cholesterol efflux in macrophages and thereby protecting against the development of atherosclerosis (Wang et al., 2001; Kunjathoor et al., 2002; Yancey et al., 2003; Kennedy et al., 2005; Moore and Tabas, 2011). Another class of proteins called ATP-binding cassette (ABC) transporters moves cholesterol outside of the cell and regulates cellular lipid homeostasis in macrophages. The ABC transporter proteins bind ATP and use the energy to drive the translocation of a diverse array of compounds across specific cellular membrane bilayers that include the endoplasmic reticulum, mitochondria, peroxisomes and plasma membrane (Dean et al., 2001; Tarr and Edwards, 2008). ABCA1 and ABCG1 are members of ABC transporter superfamily and mediate cholesterol efflux in macrophages (Moore and Tabas, 2011). In the current study, we determined whether TG induced changes in expression of genes involved in cholesterol efflux. We found that exogenous TG treated THP-1 macrophages up-regulated expression of ABCG1. Up-regulation of ABCG1 occurred through activation of the JNK and p38 MAPK pathways. Our results suggest that TG may modulate cholesterol homeostasis in THP-1 macrophages.

MATERIALS AND METHODS

Materials

Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma-Aldrich (St. Louis, MO, USA). TG emulsion (Lipofundin® MCT/LCT 20%) was purchased from B. Braun Melsungen AG (Melsungen, Germany). Lipofundin® MCT/LCT 20% was used to deliver TG into cells as previously described (Aronis et al., 2005). Trypsin-EDTA was obtained from Gibco BRL (Grand Island, NY, USA). TRIzol® for RNA isolation was obtained from Invitrogen (Carlsbad, CA, USA). Chemical inhibitors for classical PKC (RO31-7549, 0.5 μM), MEK1 (PD98059, 50 μM), PI3K (LY294002, 10 μM), p38 MAPK (SB203580, 20 μM), JNK (SP600125, 50 μM) and cRAF-1 kinase (GW5074, 0.5 μM) were purchased from Calbiochem (Darmstadt, Germany). Specific inhibitor of NF-κB (BAY11-7085, 1 μM) was purchased from Enzo Life Sciences (New York, NY, USA). Specific inhibitor of PLC (U73122, 50 μM) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Dimethyl sulfoxide (DMSO) was obtained from Sigma-Aldrich (St. Louis, MO, USA). All inhibitors were dissolved as stock solutions in DMSO and stored at -20°C prior to usage. Antibodies specific for phosphorylated JNK (p-JNK) and phosphorylated p-38 MAPK (p-p38 MAPK) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody specific for β-actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell culture

The THP-1 human acute monocytic leukemia cell line (ATCC, Manassas, VA, USA) was grown in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin and maintained at 37°C in a humidified atmosphere with 5% CO₂. To induce differentiation of THP-1 cells into macrophages, cells were seeded in 6-well plates at a density of 1 × 10⁶ cells/well and treated with PMA (200 nM) for 48 h. Thereafter, PMA-differentiated THP-1 macrophages were incubated with TG and/or chemical inhibitors.

RNA extraction and semi-quantitative reverse transcriptase PCR (RT-PCR)

Total RNA was isolated from THP-1 macrophages using TRIzol® reagent according to the manufacturer's instructions. cDNA was synthesized by reverse transcription with 2 μg total RNA, 0.25 μg of random hexamer (Invitrogen) and 200 unit of Moloney murine leukemia virus reverse transcriptase (MMLV-RT; Invitrogen) for 10 min at 25°C, 50 min at 37°C and 15 min at 70°C. cDNA was PCR amplified
using Prime Taq premix PCR kit (Genet Bio, Chungnam, Korea) for 25~50 cycles using specific primers. Primer sequences are as follows: ABCA1; 5'-CCC CTG TTT CCG TTA CCC-3' (forward), 5'-AGC CCT CAG CAT CTT GTG-3' (reverse), ABCG1; 5'-GCA GTT ACT CTG CAG AGA TG-3' (forward), 5'-CGG AAA TTC CTT TCA GGA GG-3' (reverse), SR-B1; 5'-CTG TGG GTG AGA TCA TGT GG-3' (forward), 5'-GCC AGA AGT CAA CCT TGC TC-3' (reverse). GAPDH was used as an internal control (Yoon et al., 2012). PCR products were electrophoresed on 2% (w/v) agarose gels containing 0.5 μg/mL ethidium bromide and the product size determined by comparison to 100 bp DNA ladder marker (Intron, Gyeonggi, Korea). Gel images were taken using Gel Doc™ XR+ system (Bio-Rad, Hercules, CA, USA). The PCR product band intensity was measured and normalized against GAPDH using Image Lab™ software (version 4.1, Bio-Rad).

Western-blot analysis

Cells were washed with PBS and then lysed at 4℃ with a lysis buffer containing 1% Triton X-100, protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA), phosphatase inhibitor cocktail (Roche, Basel, Switzerland) and PBS. The lysate was centrifuged at 14,000 RPM for 5 min at 4℃. The supernatant was collected and proteins were quantified using Lowry protein assay. Protein samples (60 μg per lane, but 20 μg per lane in β-actin analysis) were separated by 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. The membrane was blocked with TBST containing 5% (w/v) skim milk for 30 min and then incubated with primary antibody overnight at 4℃. Each immunoblot was then incubated with appropriate horseradish peroxidase-labeled secondary antibody (anti-mouse or anti-rabbit). The antibody-labeled proteins were visualized using ECL kit (Thermo, Waltham, MA, USA) and exposed onto X-ray film (AGPA, Mortsel, Belgium). β-actin was used as an internal control.

Statistical analysis

P-values were calculated using the Student's t-test. Values are shown as mean and standard error of the mean (SEM). Each experiment was conducted three times and the data pooled for analysis.

RESULTS

ABCG1 expression is up-regulated in TG treated THP-1 macrophage

Cholesterol accumulation in macrophages promotes atherosclerosis and several proteins are known to regulate cholesterol movement in cells. In this current study, we first assessed whether TG could affect the expression of cholesterol regulatory genes in THP-1 macrophages. PMA-induced THP-1 macrophages were treated with TG (1 mg/
(1 mg/mL) for 24 h and expression of ABCA1, ABCG1 and SR-B1 assessed by RT-PCR. We found that expression of ABCG1 was increased by TG treatment in THP-1 macrophages whereas expression of ABCA1 and SR-B1 remained unchanged (Fig. 1). These results indicate that TG treatment up-regulated mRNA expression of ABCG1 in THP-1 macrophages suggesting that TG can potentially enhance cholesterol efflux in macrophages.

TG up-regulates ABCG1 expression in THP-1 macrophages in a time- and dose-dependent manner

Since TG up-regulated ABCG1 expression in THP-1 macrophages at 24 h, we next determined when TG induced expression of ABCG1. THP-1 macrophages were treated with TG (1 mg/ml) for the indicated times (0, 3, 6, 12, 18, and 24 h) and ABCG1 expression assessed by RT-PCR. The PCR products were electrophoresed on a 2% agarose gel. (A) A representative image of ABCG1 expression. (B) Densitometry analysis of PCR products. The ABCG1 expression level was normalized to GAPDH expression. Time point 0 h was set as 100. Data are expressed as the mean ± SEM from three independent experiments. *P-values were determined by the Student’s t-test (*P<0.05, **P<0.01).
Modulation of ABCG1 expression in TG treated THP-1 macrophages is mediated by JNK, p38 MAPK and MEK1 pathways

To identify cell signaling pathways involved in up-regulation of ABCG1 in TG treated THP-1 macrophages, TG treated THP-1 macrophages were co-treated with chemical inhibitors of select cell signaling pathways and ABCG1 expression assessed by RT-PCR analysis. The following inhibitors were tested: PKC (RO31-7549), MEK1 (PD98059), NF-κB (BAY11-7085), PI3K (LY294002), JNK (SP600125), p38 MAPK (SB203580), cRAF-1 kinase (GW5074) and PLC (U73122). We found that the JNK inhibitor (SP600125) and p38 MAPK inhibitor (SB203580) dramatically blocked ABCG1 up-regulation (Fig. 4A and Fig. 4B). In contrast, the MEK1 inhibitor (PD98059) further enhanced ABCG1 expression. To confirm activation of the JNK and p38 MAPK in TG treated THP-1 macrophages, THP-1 macrophages were treated with TG (1 mg/mL) for the indicated times (0, 3, 6, 12, 18 and 24 h) and protein levels of p-JNK and p-p38 MAPK were detected by Western-blot analysis. We found that p-JNK and p-p38 MAPK were also increased in TG time-dependent manner (Fig. 4C). In particular, TG transiently activated JNK at 3 h. However, p38 MAPK was activated by TG at 6 h and remained activated for an additional 24 h. These results suggest that TG-induced up-regulation of ABCG1 expression requires activation of the JNK and p38 MAPK. Furthermore, MEK1 negatively regulates ABCG1 gene expression in TG treated THP-1 macrophages.

**DISCUSSION**

Uptake of TG and cholesterol by macrophages both contribute to development atherosclerosis. As far as we know, the results from this current study are the first to demonstrate that uptake of TG by macrophages can modulate expression of genes involved in cholesterol efflux. The key finding of our study is that TG can induce expression of the cholesterol efflux gene, ABCG1, via activation of the JNK and p38 MAPK pathways. In addition, we identified the MEK1 pathway as a negative regulator of
TG induced ABCG1 up-regulation in THP-1 macrophages. The identification of these genes will most likely provide clues for future detailed analysis by which TG impacts cholesterol homeostasis in macrophages.

Recent studies have shown that ABC transporters have important roles in efflux of endogenous cholesterolors (Tarr and Edwards, 2008; Moore and Tabas, 2011). For example, combined deficiency of ABCA1 and ABCG1 resulted in a 60% decrease in macrophage cholesterol efflux in mice (Yvan-Charvet et al., 2007; Tall et al., 2008). In the current study, TG up-regulates ABCG1. It may suggest that cholesterol efflux is enhanced in response to TG. Also, it may be possible that TG may increase uptake of cholesterol resulting in up-regulation of ABCG1 to transport excess cholesterol outside of the cells for protection of the cells. Several proteins have been described in the literature that regulates ABCG1. One such protein is the liver X receptor (LXR). LXRs are transcription factors of the nuclear receptor superfamily and functions as a whole body cholesterol sensor (Calkin and Tontonoz, 2010). The ABC transporter-mediated efflux of cholesterol is regulated by LXRs and the bile acid receptor (FXR), as heterodimers with retinoid X receptors (RXRs) (Repa et al., 2000; Dean et al., 2001). Endogenous ligands for LXR are likely to be intermediates or end products of cholesterol metabolites such as hydroxycholesterol and epoxycholesterol. It was shown that LXR-induced expression of ABCA1 and ABCG1 in macrophages is essential for the stimulation of cholesterol efflux (Huwait et al., 2011; Moore and Tabas, 2011). Also other researchers have reported LXR agonists activate several components of the JNK pathway, such as SEK1, JNK and c-Jun. In addition, dominant negative mutation of JNK pathway inhibited the LXR agonist-induced up-regulation of ABC transporter in murine macrophages (Huwait et al., 2011). Paradoxically, Nagelin et al. showed that activation of ABCG1 is down-regulated by JNK pathway and p38 MAPK pathway (Nagelin et al., 2009). These results suggest that TG could possibly induce expression of ABCG1 via LXRs and JNK pathway. As for MEK1, studies have shown that the MEK1 pathway influences LXR-inducible ABC transporter expression in macrophages (Mulay et al., 2013). Similarly, our data also shows that TG negatively regulates ABCG1 expression via MEK1 pathway. Overexpression of ABCA1 and ABCG1 protected macrophages against oxidative stress-induced cell death (Yvan-Charvet et al., 2010). In previous studies, we found that THP-1 macrophages treated with TG (1 mg/mL) for 24 h induced cell death in 30% of the cells (Son et al., 2013). It is possible that the induction of ABCG1 in TG-treated THP-1 cells may be result of a survival mechanism employed by the cells to prevent cell death.

In addition to SR-B1, macrophage scavenger receptor-1 (MSR1), MARCO and CD36 (also known as SCARB3) can all mediate the endocytosis of cholesterol by binding to modified low density lipoproteins (modified-LDLs). Although we found that SR-B1 expression was unaffected by TG treatment, it is possible that MARCO and CD36 may be affected. These possibilities will be evaluated in future experiments. In conclusion, our data showed that increase of exogenous TG induces up-regulation of ABCG1 expression through JNK and p38 MAPK pathway. These alterations maybe affects the cholesterol uptake/efflux. Although mRNA expression studies do not fully explain molecular mechanism of lipid accumulation, our data may provide further insights into the role of TG on macrophages during formation of foam cells.

REFERENCES
Feingold KR, Shigenaga JK, Kazemi MR, McDonald CM, Patzek SM, Cross AS, Moser A, Grunfeld C. Mechanisms of trigly-


